ATROPINE\HYOSCYAMINE\PHENOBARBITAL\SCOPOLAMINE HYDROBROMIDE: 73 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
73
Total FAERS Reports
3 (4.1%)
Deaths Reported
7
Hospitalizations
73
As Primary/Secondary Suspect
8
Life-Threatening
1
Disabilities
Active Ingredient: ATROPINE SULFATE\HYOSCYAMINE SULFATE\PHENOBARBITAL\SCOPOLAMINE HYDROBROMIDE ·
First Report: 20070501 · Latest Report: 202011
What Are the Most Common ATROPINE\HYOSCYAMINE\PHENOBARBITAL\SCOPOLAMINE HYDROBROMIDE Side Effects?
#1 Most Reported
Drug hypersensitivity
26 reports (35.6%)
#2 Most Reported
Apparent life threatening event
8 reports (11.0%)
#3 Most Reported
Infantile apnoea
6 reports (8.2%)
All ATROPINE\HYOSCYAMINE\PHENOBARBITAL\SCOPOLAMINE HYDROBROMIDE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Drug hypersensitivity | 26 | 35.6% | 0 | 0 |
| Apparent life threatening event | 8 | 11.0% | 0 | 0 |
| Infantile apnoea | 6 | 8.2% | 0 | 0 |
| Gastrooesophageal reflux disease | 5 | 6.9% | 0 | 0 |
| Headache | 5 | 6.9% | 0 | 1 |
Who Reports ATROPINE\HYOSCYAMINE\PHENOBARBITAL\SCOPOLAMINE HYDROBROMIDE Side Effects? Age & Gender Data
Gender: 74.5% female, 25.5% male. Average age: 59.1 years. Most reports from: US. View detailed demographics →
Is ATROPINE\HYOSCYAMINE\PHENOBARBITAL\SCOPOLAMINE HYDROBROMIDE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2007 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2014 | 4 | 0 | 1 |
| 2015 | 1 | 0 | 0 |
| 2016 | 1 | 0 | 0 |
| 2018 | 2 | 0 | 0 |
| 2020 | 1 | 0 | 0 |
What Is ATROPINE\HYOSCYAMINE\PHENOBARBITAL\SCOPOLAMINE HYDROBROMIDE Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 15 |
| Abdominal pain | 9 |
| Irritable bowel syndrome | 5 |
Official FDA Label for ATROPINE\HYOSCYAMINE\PHENOBARBITAL\SCOPOLAMINE HYDROBROMIDE
Official prescribing information from the FDA-approved drug label.